What is eccentric left ventricular hypertrophy, what causes it, and how should it be treated?

Eccentric Left Ventricular Hypertrophy

Eccentric left ventricular hypertrophy (LVH) is characterized by increased left ventricular mass with proportional chamber dilatation (increased end-diastolic volume) and a relative wall thickness ≤0.42, representing a distinct pathophysiologic pattern that requires etiology-specific treatment targeting the underlying volume overload condition.

Definition and Pathophysiology

Eccentric LVH occurs when cardiac myocytes elongate in series (adding sarcomeres longitudinally) in response to chronic volume overload, resulting in:

• Increased LV mass (hypertrophy)
• Increased LV cavity size (dilatation)
• Normal or decreased relative wall thickness (RWT ≤0.42)
• Often a more spherical ventricular geometry 1

The ESC Working Group emphasizes that "hypertrophy" technically refers to individual cardiac myocyte changes, and the whole-heart phenomenon should be termed "myocardial remodeling" 2. However, eccentric LVH remains the clinically accepted term for this specific geometric pattern.

Primary Causes

Volume Overload States

The most common etiologies include:

• Chronic aortic regurgitation - The classic cause, where progressive LV dilatation initially compensates for regurgitant volume but eventually leads to contractile dysfunction and interstitial fibrosis 3
• Mitral regurgitation - Chronic volume overload from valvular incompetence
• High-output states - Anemia, arteriovenous fistulas, thyrotoxicosis
• Obesity - Creates eccentric LVH regardless of blood pressure level through increased intravascular volume and cardiac output 4

Heart Failure Phenotypes

• HFpEF subset - Approximately 12% of heart failure with preserved ejection fraction patients demonstrate eccentric rather than concentric hypertrophy, representing a distinct pathophysiologic subset with reduced contractility and increased LV compliance 1
• Physiologic adaptation - Endurance athletes (particularly cyclists and triathletes) develop eccentric LVH as a beneficial adaptation, with up to 94% prevalence in some disciplines 5

Clinical Significance and Prognosis

Eccentric LVH carries substantial prognostic implications:

• Increased SCD risk - Strong independent risk factor for sudden cardiac death regardless of ejection fraction 6
• Contractile dysfunction - Associated with reduced LVEF and decreased systolic blood pressure-to-end-systolic volume ratio compared to concentric patterns 1
• Transition to pathologic state - In aortic regurgitation, cellular hypertrophy >30 microns and interstitial fibrosis >10% mark the transition from physiologic to pathologic remodeling, often occurring earlier than previously recognized 3

Diagnostic Approach

Echocardiography is the first-line imaging modality 2. Key measurements include:

• LV mass index (increased)
• LV end-diastolic volume index (increased)
• Relative wall thickness = (2 × posterior wall thickness)/LV end-diastolic diameter (≤0.42)
• Assessment of systolic function (LVEF, ESS/ESVI ratio)
• Evaluation of diastolic function (E/e' ratio, filling pressures)

Treatment Strategy

Etiology-Specific Management

Treatment must target the underlying cause 7:

For Valvular Disease (Aortic/Mitral Regurgitation)

• Surgical intervention is indicated before irreversible myocardial dysfunction develops
• Critical thresholds: ESVI ≥70 ml/m² signals advanced cellular hypertrophy and warrants consideration for valve surgery 3
• Monitor for declining contractility (ESS/ESVI ratio) and rising interstitial fibrosis

For Hypertension with Eccentric Pattern

This represents a distinct hemodynamic profile:

• Lower peripheral vascular resistance
• Increased stroke volume
• Low plasma renin activity
• Enhanced sympathetic activity 8

Eccentric hypertrophy in hypertension is refractory to both losartan and atenolol 8, unlike concentric hypertrophy which responds well to angiotensin II antagonists. Consider:

• Calcium channel blockers (favorable hemodynamic and risk profile effects) 4
• Indapamide if diuretic therapy needed 4

For Obesity-Related Eccentric LVH

• Aggressive weight reduction is the primary intervention 4
• Sodium restriction
• Calcium channel blockers preferred over traditional diuretics (except indapamide) due to better metabolic profile 4

For HFpEF with Eccentric Pattern

These patients are pathophysiologically similar to HFrEF and may benefit from HFrEF therapies 1, including:

• ACE inhibitors/ARBs
• Beta-blockers
• Mineralocorticoid receptor antagonists
• SGLT2 inhibitors (based on contemporary HFrEF evidence)

Common Pitfalls

• Assuming all LVH responds similarly to treatment - Eccentric and concentric patterns have fundamentally different hemodynamic profiles and therapeutic responses 8
• Delaying valve surgery in chronic regurgitation - Waiting for symptoms risks irreversible myocardial fibrosis and contractile dysfunction 3
• Treating obesity-hypertension eccentric LVH with standard diuretics - May worsen metabolic profile without addressing the dual hemodynamic burden 4
• Ignoring eccentric LVH in HFpEF - This subset requires different management than typical concentric HFpEF 1

Monitoring Parameters

Track these to assess disease progression and treatment response:

• Serial LV volumes and mass
• Contractile indices (LVEF, ESS/ESVI)
• Diastolic function parameters
• Exercise capacity (peak VO2, ventilatory power) 9
• Arrhythmia burden given elevated SCD risk 6